<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MAXZIDE-25- triamterene and hydrochlorothiazide tablet </strong><br><strong>MAXZIDE- triamterene and hydrochlorothiazide tablet </strong><br>Mylan Pharmaceuticals Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_9d2aaa13-b585-4cf3-8eb0-be789fdb497d"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">MAXZIDE<span class="Sup">®</span> (triamterene and hydrochlorothiazide) combines triamterene, a potassium-conserving diuretic, with the natriuretic agent, hydrochlorothiazide.</p>
<p>Each MAXZIDE<span class="Sup">®</span> tablet contains:</p>
<p>Triamterene, USP ............................................................................... 75 mg<br>Hydrochlorothiazide, USP .................................................................. 50 mg</p>
<p>Each MAXZIDE<span class="Sup">®</span>-25 MG tablet contains:</p>
<p>Triamterene, USP ................................................................................ 37.5 mg<br>Hydrochlorothiazide, USP ..................................................................  25 mg</p>
<p>MAXZIDE<span class="Sup">®</span> and MAXZIDE<span class="Sup">®</span>-25 MG tablets for oral administration contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, D&amp;C Yellow No. 10 Aluminum Lake, magnesium stearate, microcrystalline cellulose, powdered cellulose and sodium lauryl sulfate. MAXZIDE<span class="Sup">®</span>-25 MG tablets also contain FD&amp;C Blue No. 1 Aluminum Lake.</p>
<p>Triamterene is 2,4,7-triamino-6-phenylpteridine. Triamterene is practically insoluble in water, benzene, chloroform, ether and dilute alkali hydroxides. It is soluble in formic acid and sparingly soluble in methoxyethanol. Triamterene is very slightly soluble in acetic acid, alcohol and dilute mineral acids. Its molecular weight is 253.27. Its structural formula is:</p>
<div class="Figure">
<a name="id420"></a><img alt="Triamterene Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e92eda49-861e-4c79-b446-ec1213151d92&amp;name=2279e030-7857-457a-bc78-a19dcd04ef91-01.jpg">
</div>
<p>Hydrochlorothiazide is 6-chloro-3,4-dihydro-2<span class="Italics">H</span>-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is slightly soluble in water and freely soluble in sodium hydroxide solution, n-butylamine and dimethylformamide. It is sparingly soluble in methanol and insoluble in ether, chloroform and dilute mineral acids. Its molecular weight is 297.73. Its structural formula is:</p>
<div class="Figure">
<a name="id423"></a><img alt="Hydrochlorothiazide Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e92eda49-861e-4c79-b446-ec1213151d92&amp;name=2279e030-7857-457a-bc78-a19dcd04ef91-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_984ac00a-b26f-4a22-a8d5-86950ca66b14"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">MAXZIDE (triamterene and hydrochlorothiazide) is a diuretic, antihypertensive drug product, principally due to its hydrochlorothiazide component; the triamterene component of MAXZIDE reduces the excessive potassium loss which may occur with hydrochlorothiazide use.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8cb93d50-90ba-431f-9bc3-e9f602564de6"></a><a name="section-2.1"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<p class="First">Hydrochlorothiazide is a diuretic and antihypertensive agent. It blocks the renal tubular absorption of sodium and chloride ions. This natriuresis and <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> is accompanied by a secondary loss of potassium and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>. Onset of hydrochlorothiazide’s <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuretic effect</span> occurs within 2 hours and the peak action takes place in 4 hours. Diuretic activity persists for approximately 6 to 12 hours.</p>
<p>The exact mechanism of hydrochlorothiazide’s antihypertensive action is not known although it may relate to the excretion and redistribution of body sodium. Hydrochlorothiazide does not affect normal blood pressure.</p>
<p>Following oral administration, peak hydrochlorothiazide plasma levels are attained in approximately 2 hours. It is excreted rapidly and unchanged in the urine.</p>
<p>Well controlled studies have demonstrated that doses of hydrochlorothiazide as low as 25 mg given once daily are effective in treating <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, but the dose-response has not been clearly established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a521362-e882-423e-8986-d7a94dd76810"></a><a name="section-2.2"></a><p></p>
<h2>Triamterene</h2>
<p class="First">Triamterene is a potassium-conserving (antikaliuretic) diuretic with relatively weak natriuretic properties. It exerts its <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuretic effect</span> on the distal renal tubule to inhibit the reabsorption of sodium in exchange for potassium and hydrogen. With this action, triamterene increases sodium excretion and reduces the excessive loss of potassium and hydrogen associated with hydrochlorothiazide. Triamterene is not a competitive antagonist of the mineralocorticoids and its potassium-conserving effect is observed in patients with Addison’s disease, i.e., without aldosterone. Triamterene’s onset and duration of activity is similar to hydrochlorothiazide. No predictable antihypertensive effect has been demonstrated with triamterene. </p>
<p>Triamterene is rapidly absorbed following oral administration. Peak plasma levels are achieved within one hour after dosing. Triamterene is primarily metabolized to the sulfate conjugate of hydroxytriamterene. Both the plasma and urine levels of this metabolite greatly exceed triamterene levels.</p>
<p>The amount of triamterene added to 50 mg of hydrochlorothiazide in MAXZIDE tablets was determined from steady-state dose-response evaluations in which various doses of liquid preparations of triamterene were administered to hypertensive persons who developed <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> with hydrochlorothiazide (50 mg given once daily). Single daily doses of 75 mg triamterene resulted in greater increases in serum potassium than lower doses (25 mg and 50 mg), while doses greater than 75 mg of triamterene resulted in no additional elevations in serum potassium levels. The amount of triamterene added to the 25 mg of hydrochlorothiazide in MAXZIDE-25 MG tablets was also determined from steady-state dose-response evaluations in which various doses of liquid preparations of triamterene were administered to hypertensive persons who developed <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> with hydrochlorothiazide (25 mg given once daily). Single daily doses of 37.5 mg triamterene resulted in greater increases in serum potassium than a lower dose (25 mg), while doses greater than 37.5 mg of triamterene, i.e., 75 mg and 100 mg, resulted in no additional elevations in serum potassium levels. The dose-response relationship of triamterene was also evaluated in patients rendered hypokalemic by hydrochlorothiazide given 25 mg twice daily. Triamterene given twice daily increased serum potassium levels in a dose related fashion. However, the combination of triamterene and hydrochlorothiazide given twice daily also appeared to produce an increased frequency of elevation in serum BUN and creatinine levels. The largest increases in serum potassium, BUN and creatinine in this study were observed with 50 mg of triamterene given twice daily, the largest dose tested. Ordinarily, triamterene does not entirely compensate for the kaliuretic effect of hydrochlorothiazide and some patients may remain hypokalemic while receiving triamterene and hydrochlorothiazide. In some individuals, however, it may induce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (see <a href="#i4i_warnings_id_96fcf671-8413-4ab7-aef4-c391fd368a05">WARNINGS</a>).</p>
<p>The triamterene and hydrochlorothiazide components of MAXZIDE and MAXZIDE-25 MG are well absorbed and are bioequivalent to liquid preparations of the individual components administered orally. Food does not influence the absorption of triamterene or hydrochlorothiazide from MAXZIDE or MAXZIDE-25 MG tablets. The hydrochlorothiazide component of MAXZIDE is bioequivalent to single entity hydrochlorothiazide tablet formulations.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_acbf50fd-7e2e-4c54-99df-987e5aeada95"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">This fixed combination drug is not indicated for the initial therapy of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> except in individuals in whom the development of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> cannot be risked. </span></p>
<dl>
<dt>•</dt>
<dd>MAXZIDE (triamterene and hydrochlorothiazide) is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> in patients who develop <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> on hydrochlorothiazide alone.</dd>
<dt>•</dt>
<dd>MAXZIDE is also indicated for those patients who require a thiazide diuretic and in whom the development of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, etc.).</dd>
</dl>
<p>MAXZIDE may be used alone or in combination with other antihypertensive drugs, such as beta-blockers. Since MAXZIDE (triamterene and hydrochlorothiazide) may enhance the actions of these drugs, dosage adjustments may be necessary. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c3c83d4-4eda-478d-a8f9-9f20a1b213d1"></a><a name="section-3.1"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of <span class="product-label-link" type="condition" conceptid="439393" conceptname="Pre-eclampsia">toxemia of pregnancy</span>, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. </p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> is due to pathologic causes, just as they are in the absence of pregnancy. <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">Dependent edema</span> in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span> which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, including <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, in the majority of pregnant women. If this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> produces <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, increased recumbency will often provide relief. In rare instances, this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> may cause extreme <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. </p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_521ad870-4c3a-4626-a2f4-226506c58ac4"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_52d078de-d1b3-4075-8336-dad5fb5ef25d"></a><a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h2>
<p class="First">MAXZIDE (triamterene and hydrochlorothiazide) should not be used in the presence of elevated serum potassium levels (greater than or equal to 5.5 mEq/liter). If <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> develops, this drug should be discontinued and a thiazide alone should be substituted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3110e058-edb9-445b-a9f4-60d874dfed39"></a><a name="section-4.2"></a><p></p>
<h2>Antikaliuretic Therapy or Potassium Supplementation</h2>
<p class="First">MAXZIDE should not be given to patients receiving other potassium-conserving agents such as spironolactone, amiloride or other formulations containing triamterene. Concomitant potassium supplementation in the form of medication, potassium-containing salt substitute or potassium-enriched diets should also not be used. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3c476675-c5dd-4ab9-afb1-dbe5cf1bce6c"></a><a name="section-4.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">MAXZIDE is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, acute and <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal insufficiency</span> or significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_958ea3bf-5551-49d9-82e0-e2a96c0209c3"></a><a name="section-4.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">MAXZIDE should not be used in patients who are hypersensitive to triamterene or hydrochlorothiazide or other sulfonamide-derived drugs. </p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_96fcf671-8413-4ab7-aef4-c391fd368a05"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Warning">
<a name="id_183e450a-5045-4f88-93b0-9aa927342676"></a><a name="section-5.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span></p>
<p>Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-conserving diuretic combinations, including MAXZIDE. <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> is more likely to occur in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (even without evidence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>), or elderly or severely ill patients. Since uncorrected <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may be fatal, serum potassium levels must be monitored at frequent intervals especially in patients first receiving MAXZIDE, when dosages are changed or with any illness that may influence renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_41d8417e-4356-41fd-80a0-319c7a458ba0"></a><a name="section-5.1"></a><p></p>
<p class="First">If <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> is suspected, (warning signs include <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4193951" conceptname="Flaccid paralysis">flaccid paralysis</span> of the extremities, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>) an electrocardiogram (ECG) should be obtained. However, it is important to monitor serum potassium levels because mild <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may not be associated with ECG changes.</p>
<p>If <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> is present, MAXZIDE (triamterene and hydrochlorothiazide) should be discontinued immediately and a thiazide alone should be substituted. If the serum potassium exceeds 6.5 mEq/liter, more vigorous therapy is required. The clinical situation dictates the procedures to be employed. These include the intravenous administration of calcium chloride solution, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> solution and/or the oral or parenteral administration of glucose with a rapid-acting insulin preparation. Cationic exchange resins such as sodium polystyrene sulfonate may be orally or rectally administered. Persistent <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may require dialysis. </p>
<p>The development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> associated with potassium-sparing diuretics is accentuated in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <a href="#i4i_contraindications_id_521ad870-4c3a-4626-a2f4-226506c58ac4">CONTRAINDICATIONS</a>). Patients with mild renal functional impairment should not receive this drug without frequent and continuing monitoring of serum electrolytes. Cumulative drug effects may be observed in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. The renal clearances of hydrochlorothiazide and the pharmacologically active metabolite of triamterene, the sulfate ester of hydroxytriamterene, have been shown to be reduced and the plasma levels increased following MAXZIDE (triamterene and hydrochlorothiazide) administration to elderly patients and patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. </p>
<p><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> has been reported in diabetic patients with the use of potassium-conserving agents even in the absence of apparent <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Accordingly, MAXZIDE (triamterene and hydrochlorothiazide) should be avoided in diabetic patients. If it is employed, serum electrolytes must be frequently monitored.</p>
<p>Because of the potassium-sparing properties of angiotensin-converting enzyme (ACE) inhibitors, MAXZIDE should be used cautiously, if at all, with these agents (see <a href="#i4i_interactions_id_3b36b059-88da-4fb2-97d9-fce5e9be4e8f">PRECAUTIONS: Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a0da47f3-269e-4fc5-bdd8-a79c35797f0f"></a><a name="section-5.2"></a><p></p>
<h2>Metabolic or <span class="product-label-link" type="condition" conceptid="4048509" conceptname="Respiratory acidosis">Respiratory Acidosis</span></h2>
<p class="First">Potassium-conserving therapy should also be avoided in severely ill patients in whom respiratory or <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> may occur. <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span> may be associated with rapid elevations in serum potassium levels. If MAXZIDE is employed, frequent evaluations of acid/base balance and serum electrolytes are necessary. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_49316454-3efd-4919-b75f-196de51f57c2"></a><a name="section-5.3"></a><p></p>
<h2>Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> and acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Symptoms include acute onset of decreased visual acuity or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> can lead to permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> may include a history of sulfonamide or <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_33502d24-19a7-46d0-9c66-795e33bfe145"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_ffd1957b-c451-4535-b8d6-62c9128aaa1a"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4d713d75-4d48-48e3-b76b-743220029225"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Imbalance</span> and BUN Increases</span></span></h3>
<p class="First">Patients receiving MAXZIDE (triamterene and hydrochlorothiazide) should be carefully monitored for fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalances</span>, i.e., <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>. Determination of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be performed at appropriate intervals. Serum and urine electrolyte determinations are especially important and should be frequently performed when the patient is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or receiving parenteral fluids. Warning signs or symptoms of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> include: dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, muscular <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>Any chloride deficit during thiazide therapy is generally mild and usually does not require any specific treatment except under extraordinary circumstances (as in liver disease or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>). Dilutional <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances when the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is life threatening. In actual <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, appropriate replacement is the therapy of choice. </p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may develop with thiazide therapy, especially with brisk <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, when severe cirrhosis is present, or during concomitant use of corticosteroids, ACTH, amphotericin B or after prolonged thiazide therapy. However, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> of this type is usually prevented by the triamterene component of MAXZIDE (triamterene and hydrochlorothiazide).</p>
<p>Interference with adequate oral electrolyte intake will also contribute to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> can sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>).</p>
<p>MAXZIDE (triamterene and hydrochlorothiazide) may produce an elevated blood urea nitrogen level (BUN), creatinine level or both. This is probably not the result of renal toxicity but is secondary to a reversible reduction of the glomerular filtration rate or a depletion of the intravascular fluid volume. Elevations in BUN and creatinine levels may be more frequent in patients receiving divided dose diuretic therapy. Periodic BUN and creatinine determinations should be made especially in elderly patients, patients with suspected or confirmed <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> or renal insufficiencies. If <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> increases, MAXZIDE (triamterene and hydrochlorothiazide) should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a0b1cc3b-ece3-474f-8bfe-77d279b06f0f"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">Hepatic Coma</span></span></span></h3>
<p class="First">MAXZIDE should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_90551697-d7b8-4e67-ac6e-d934dd62e612"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Renal Stones</span></span></span></h3>
<p class="First">Triamterene has been reported in <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal stones</span> in association with other calculus components. MAXZIDE should be used with caution in patients with histories of renal lithiasis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_49af790d-6b37-4133-9e5f-e8897634764a"></a><a name="section-6.1.4"></a><p></p>
<h3><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">Folic Acid Deficiency</span></span></span></h3>
<p class="First">Triamterene is a weak folic acid antagonist and may contribute to the appearance of <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastosis</span> in instances where folic acid stores are decreased. In such patients, periodic blood elevations are recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_559355c0-6d42-4ee2-9762-2b6b57ee499b"></a><a name="section-6.1.5"></a><p></p>
<h3><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span></span></span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> may occur or acute <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> may be precipitated in certain patients receiving thiazide therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f309af32-5e94-491d-ad41-83e2bfc21939"></a><a name="section-6.2"></a><p></p>
<h2>Metabolic and Endocrine Effects</h2>
<p class="First">The thiazides may decrease serum PBI levels without signs of thyroid disturbance.</p>
<p>Calcium excretion is decreased by thiazides. Pathological changes in the parathyroid gland with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> and <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> have been observed in a few patients on prolonged thiazide therapy. The common complications of <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> such as renal lithiasis, bone resorption, and <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span> have not been seen. Thiazides should be discontinued before carrying out tests for parathyroid function.</p>
<p>Insulin requirements in diabetic patients may be increased, decreased or unchanged. <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus which has been latent may become manifest during thiazide administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c6ca7b32-992a-4ce7-b8c6-7c75dbd104f3"></a><a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Sensitivity reactions to thiazides may occur in patients with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p>Possible exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> by thiazides has been reported.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_3b36b059-88da-4fb2-97d9-fce5e9be4e8f"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Thiazides may add to or potentiate the action of other antihypertensive drugs.</p>
<p>The thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. Thiazides have also been shown to increase the responsiveness to tubocurarine.</p>
<p>Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Refer to the package insert on lithium before use of such concomitant therapy.</p>
<p><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> has been reported in a few patients receiving indomethacin and formulations containing triamterene and hydrochlorothiazide. Caution is therefore advised when administering non-steroidal anti-inflammatory agents with MAXZIDE (triamterene and hydrochlorothiazide).</p>
<p>Potassium-sparing agents should be used very cautiously, if at all, in conjunction with angiotensin-converting enzyme (ACE) inhibitors due to a greatly increased risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. Serum potassium should be monitored frequently.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cdc8dcca-dade-4b39-ba70-f64b062982b5"></a><a name="section-6.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Triamterene and quinidine have similar fluorescence spectra; thus MAXZIDE (triamterene and hydrochlorothiazide) may interfere with the measurement of quinidine. </p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_bbe7a0fc-8ace-4efc-9a9c-cee19d18943a"></a><a name="section-6.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c9b3ef25-aac8-41bf-aad6-1b3f0715006b"></a><a name="section-6.6.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Carcinogenesis</span></span></h3>
<p class="First">Long-term studies with MAXZIDE, the triamterene/hydrochlorothiazide combination, have not been conducted.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8fca023e-d7de-4b3e-9d10-2f5883cb7c00"></a><a name="section-6.6.1.1"></a><p></p>
<h4>Triamterene</h4>
<p class="First">In studies conducted under the auspices of the National Toxicology Program, groups of rats were fed diets containing 0, 150, 300 or 600 ppm triamterene, and groups of mice were fed diets containing 0, 100, 200 or 400 ppm triamterene. Male and female rats exposed to the highest tested concentration received triamterene at about 25 and 30 mg/kg/day, respectively. Male and female mice exposed to the highest tested concentration received triamterene at about 45 and 60 mg/kg/day, respectively.</p>
<p>There was an increased incidence of hepatocellular neoplasia (primarily <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>) in male and female mice at the highest dosage level. These doses represent 7.5 times and 10 times the MRHD of 300 mg/kg (or 6 mg/kg/day based on a 50 kg patient) for male and female mice, respectively when based on body-weight and 0.7 times and 0.9 times the MRHD when based on body-surface area. Although hepatocellular neoplasia (exclusively <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>) in the rat study was limited to triamterene-exposed males, incidence was not dose dependent and there was no statistically significant difference from control incidence at any dose level.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2a7c498-2ee7-48d3-929b-1926aae30d04"></a><a name="section-6.6.1.2"></a><p></p>
<h4>Hydrochlorothiazide</h4>
<p class="First">Two-year feeding studies in mice and rats, conducted under the auspices of the National Toxicology Program (NTP), treated mice and rats with doses of hydrochlorothiazide up to 600 and 100 mg/kg/day, respectively. On a body-weight basis, these doses are 600 times (in mice) and 100 times (in rats) the Maximum Recommended Human Dose (MRHD) for the hydrochlorothiazide component of MAXZIDE (50 mg/day or 1 mg/kg/day based on a 50 kg patient). On the basis of body-surface area, these doses are 56 times (in mice) and 21 times (in rats) the MRHD. These studies uncovered no evidence of carcinogenic potential of hydrochlorothiazide in rats or female mice, but there was equivocal evidence of hepatocarcinogenicity in male mice.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6026a766-c844-4ebc-9f50-dc22fad376d9"></a><a name="section-6.6.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Mutagenesis</span></span></h3>
<p class="First">Studies of the mutagenic potential of MAXZIDE, the triamterene/hydrochlorothiazide combination, have not been performed.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a15f52d0-9306-4c5b-bb1d-2be95a726a79"></a><a name="section-6.6.2.1"></a><p></p>
<h4>Triamterene</h4>
<p class="First">Triamterene was not mutagenic in bacteria (<span class="Italics">S. typhimurium</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 98, TA 100, TA 1535 or TA 1537) with or without metabolic activation. It did not induce chromosomal aberrations in Chinese hamster ovary (CHO) cells <span class="Italics">in vitro</span> with or without metabolic activation, but it did induce sister chromatid exchanges in CHO cells <span class="Italics">in vitro</span> with and without metabolic activation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b5a437da-3927-44ff-b0ac-ac7719989547"></a><a name="section-6.6.2.2"></a><p></p>
<h4>Hydrochlorothiazide</h4>
<p class="First">Hydrochlorothiazide was not genotoxic in <span class="Italics">in vitro </span>assays using <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 98, TA 100, TA 1535, TA 1537 and TA 1538 of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> (the Ames test), in the Chinese hamster ovary (CHO) test for chromosomal aberrations, or in <span class="Italics">in vivo </span>assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the <span class="Italics">Drosophila</span> sex-linked recessive lethal trait gene. Positive test results were obtained in the <span class="Italics">in vitro</span> CHO sister chromatid exchange (clastogenicity) test, and in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell (mutagenicity) assays, using concentrations of hydrochlorothiazide of 43 to 1300 mcg/mL. Positive test results were also obtained in the <span class="Italics">Aspergillus nidulans</span> nondisjunction assay using an unspecified concentration of hydrochlorothiazide.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0c6a7cdd-c02c-4882-adbf-049e58c41530"></a><a name="section-6.6.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Impairment of Fertility</span></span></h3>
<p class="First">Studies of the effects of MAXZIDE, the triamterene/hydrochlorothiazide combination, or of triamterene alone on animal reproductive function have not been conducted.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9d832e58-23b9-4b8d-8de3-1dcab8cf2176"></a><a name="section-6.6.3.1"></a><p></p>
<h4>Hydrochlorothiazide</h4>
<p class="First">Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg/day, respectively, prior to mating and throughout gestation. Corresponding multiples of the MRHD are 100 (mice) and 4 (rats) on the basis of body-weight and 9.4 (mice) and 0.8 (rats) on the basis of body-surface area.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1d2fe3e9-3aa1-4b32-b9df-1bf700b2046b"></a><a name="section-6.7"></a><p></p>
<h2>Pregnancy: Category C</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_c1cbacc1-26a0-4513-8124-506286e03ebe"></a><a name="section-6.7.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Teratogenic Effects. Category C</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ca8b78f2-b51c-4a19-9842-ae969b07b0a2"></a><a name="section-6.7.1.1"></a><p></p>
<h4>MAXZIDE</h4>
<p class="First">Animal reproduction studies to determine the potential for fetal harm by MAXZIDE have not been conducted. Nevertheless, a One Generation Study in the rat approximated MAXZIDE’s composition by using a 1:1 ratio of triamterene to hydrochlorothiazide (30:30 mg/kg/day). There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> at those doses that were, on a body-weight basis, 15 and 30 times, respectively, the MRHD, and, on the basis of body-surface area, 3.1 and 6.2 times, respectively, the MRHD.</p>
<p>The safe use of MAXZIDE in pregnancy has not been established since there are no adequate and well controlled studies with MAXZIDE in pregnant women. MAXZIDE should be used during pregnancy only if the potential benefit justifies the risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a07670c0-81f7-448d-a196-21790e02c4e1"></a><a name="section-6.7.1.2"></a><p></p>
<h4>Triamterene</h4>
<p class="First">Reproduction studies have been performed in rats at doses as high as 20 times the Maximum Recommended Human Dose (MRHD) on the basis of body-weight, and 6 times the MRHD on the basis of body-surface area without evidence of harm to the fetus due to triamterene.</p>
<p>Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b4663072-c94c-47a7-8a58-8c2fd03716fd"></a><a name="section-6.7.1.3"></a><p></p>
<h4>Hydrochlorothiazide</h4>
<p class="First">Hydrochlorothiazide was orally administered to pregnant mice and rats during respective periods of major organogenesis at doses up to 3000 and 1000 mg/kg/day, respectively. At these doses, which are multiples of the MRHD equal to 3000 for mice and 1000 for rats, based on body-weight, and equal to 282 for mice and 206 for rats, based on body-surface area, there was no evidence of harm to the fetus. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_c19f2af8-c8f0-4e67-8bd6-c9f2e0c5e89d"></a><a name="section-6.7.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Nonteratogenic Effects</span></span></h3>
<p class="First">Thiazides and triamterene have been shown to cross the placental barrier and appear in cord blood. The use of thiazides and triamterene in pregnant women requires that the anticipated benefits be weighed against possible hazards to the fetus. These hazards include fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions that have occurred in the adult.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_5be9d7a0-8ef9-485c-a2cd-7f694a51f759"></a><a name="section-6.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Thiazides and triamterene in combination have not been studied in nursing mothers. Triamterene appears in animal milk and this may occur in humans. Thiazides are excreted in human breast milk. If use of the combination drug product is deemed essential, the patient should stop nursing.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_398a3c82-3e45-4548-9244-92e5401aa2f6"></a><a name="section-6.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_d292ca42-619d-4094-a582-11d42315721b"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Side effects observed in association with the use of MAXZIDE, other combination products containing triamterene/hydrochlorothiazide, and products containing triamterene or hydrochlorothiazide include the following:</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, appetite disturbance, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste alteration</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>, cramping.</p>
<p><span class="Bold">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>.</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (may be aggravated by alcohol, barbiturates or narcotics).</p>
<p><span class="Bold">Renal:</span> <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">acute interstitial nephritis</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal stones</span> composed of triamterene in association with other calculus materials, <span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">urine discoloration</span>. </p>
<p><span class="Bold">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> and <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastosis</span>.</p>
<p><span class="Bold">Ophthalmic:</span> <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>, transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>.</p>
<p><span class="Bold">Other:</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, decreased sexual performance and <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>.</p>
<p>Whenever adverse reactions are moderate to severe, therapy should be reduced or withdrawn.</p>
<p><span class="Bold">Altered Laboratory Findings:</span></p>
<p><span class="Bold"><span class="Italics">Serum Electrolytes:</span></span> <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span> (see <a href="#i4i_warnings_id_96fcf671-8413-4ab7-aef4-c391fd368a05">WARNINGS</a> and <a href="#i4i_precautions_id_33502d24-19a7-46d0-9c66-795e33bfe145">PRECAUTIONS</a>).</p>
<p><span class="Bold"><span class="Italics">Creatinine, Blood Urea Nitrogen:</span></span> Reversible elevations in BUN and serum creatinine have been observed in hypertensive patients treated with MAXZIDE.</p>
<p><span class="Bold"><span class="Italics">Glucose:</span></span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (see <a href="#i4i_precautions_id_33502d24-19a7-46d0-9c66-795e33bfe145">PRECAUTIONS</a>).</p>
<p><span class="Bold"><span class="Italics">Serum Uric Acid, PBI and Calcium:</span></span> (see <a href="#i4i_precautions_id_33502d24-19a7-46d0-9c66-795e33bfe145">PRECAUTIONS</a>).</p>
<p><span class="Bold"><span class="Italics">Other:</span></span> Elevated liver enzymes have been reported in patients receiving MAXZIDE.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_83568070-903d-43d6-9915-375e65b26146"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">No specific data are available regarding MAXZIDE (triamterene and hydrochlorothiazide) overdosage in humans and no specific antidote is available.</p>
<p>Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalances</span> are the most important concern. Excessive doses of the triamterene component may elicit <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and possibly <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Overdosing with hydrochlorothiazide has been associated with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> (may progress to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>) and <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span>. Treatment is symptomatic and supportive. Therapy with MAXZIDE (triamterene and hydrochlorothiazide) should be discontinued. Induce <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or institute gastric lavage. Monitor serum electrolyte levels and fluid balance. Institute supportive measures as required to maintain hydration, electrolyte balance, respiratory, cardiovascular and renal function.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_fc4d2a21-74eb-4b87-9c1c-a03dc7d94544"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The usual dose of MAXZIDE-25 MG is one or two tablets daily, given as a single dose, with appropriate monitoring of serum potassium (see <a href="#i4i_warnings_id_96fcf671-8413-4ab7-aef4-c391fd368a05">WARNINGS</a>). The usual dose of MAXZIDE is one tablet daily, with appropriate monitoring of serum potassium (see <a href="#i4i_warnings_id_96fcf671-8413-4ab7-aef4-c391fd368a05">WARNINGS</a>). There is no experience with the use of more than one MAXZIDE tablet daily or more than two MAXZIDE-25 MG tablets daily. Clinical experience with the administration of two MAXZIDE-25 MG tablets daily in divided doses (rather than as a single dose) suggests an increased risk of <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> and renal dysfunction.</p>
<p>Patients receiving 50 mg of hydrochlorothiazide who become hypokalemic may be transferred to MAXZIDE (triamterene and hydrochlorothiazide) directly. Patients receiving 25 mg hydrochlorothiazide who become hypokalemic may be transferred to MAXZIDE-25 MG (37.5 mg triamterene/25 mg hydrochlorothiazide) directly.</p>
<p>In patients requiring hydrochlorothiazide therapy and in whom <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> cannot be risked therapy may be initiated with MAXZIDE-25 MG. If an optimal blood pressure response is not obtained with MAXZIDE-25 MG, the dose should be increased to two MAXZIDE-25 MG tablets daily as a single dose, or one MAXZIDE tablet daily. If blood pressure still is not controlled, another antihypertensive agent may be added (see <a href="#i4i_interactions_id_3b36b059-88da-4fb2-97d9-fce5e9be4e8f">PRECAUTIONS: Drug Interactions</a>).</p>
<p>Clinical studies have shown that patients taking less bioavailable formulations of triamterene and hydrochlorothiazide in daily doses of 25 mg to 50 mg hydrochlorothiazide and 50 mg to 100 mg triamterene may be safely changed to one MAXZIDE-25 MG tablet daily. All patients changed from less bioavailable formulations to MAXZIDE should be monitored clinically and for serum potassium after the transfer.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_536f362d-c1e8-4e49-8428-ee584b95cc22"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">MAXZIDE<span class="Sup">®</span> tablets (triamterene and hydrochlorothiazide tablets, USP) are yellow bow-tie shaped, single scored tablets with <span class="Bold">B </span>to the left of the score and <span class="Bold">M8 </span>to the right of the score on one side of the tablet and <span class="Bold">MAXZIDE</span> on the other side. Each tablet contains 75 mg of triamterene, USP and 50 mg of hydrochlorothiazide, USP. They are supplied as follows:</p>
<p>NDC 0378-0460-01<br>bottles of 100 tablets</p>
<p>MAXZIDE<span class="Sup">®</span>-25 MG tablets (triamterene and hydrochlorothiazide tablets, USP) are green bow-tie shaped, single scored tablets with <span class="Bold">B</span> to the left of the score and <span class="Bold">M9</span> to the right of the score on one side of the tablet and <span class="Bold">MAXZIDE</span> on the other side. Each tablet contains 37.5 mg of triamterene, USP and 25 mg of hydrochlorothiazide, USP. They are supplied as follows: </p>
<p>NDC 0378-0464-01<br>bottles of 100 tablets</p>
<p><span class="Bold">Store at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from light. </span></p>
<p>Dispense in a tight, light-resistant, child-resistant container.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.<br></span>Morgantown, WV  26505 U.S.A.</p>
<p>REVISED SEPTEMBER 2015<br>BKMAX:R10</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_aded8b55-3ad8-4117-bd3e-26cda538fbdd"></a><a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 37.5 mg / 25 mg </h1>
<p class="First"><span class="Bold">NDC 0378-0464-01</span></p>
<p><span class="Bold"><span class="Italics">MAXZIDE<span class="Sup">®</span>-25MG</span></span><br><span class="Bold">(triamterene and</span><br><span class="Bold">hydrochlorothiazide</span><br><span class="Bold">tablets, USP)</span><br><span class="Bold">37.5 mg/</span><br><span class="Bold">25 mg</span></p>
<p><span class="Bold">Rx only    100 Tablets</span></p>
<p>Each tablet contains 37.5 mg<br>of triamterene, USP and 25 mg<br>of hydrochlorothiazide, USP.</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p><span class="Bold">Usual Adult Dosage: </span>See <br>accompanying prescribing <br>information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RBK0464A2</span></p>
<div class="Figure">
<a name="id1144695277"></a><img alt="Maxzide-25 37.5 mg/25 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e92eda49-861e-4c79-b446-ec1213151d92&amp;name=image-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_23c7c328-0a64-4615-9cbb-d3a91e441d2d"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 75 mg / 50 mg </h1>
<p class="First"><span class="Bold">NDC 0378-0460-01</span></p>
<p><span class="Bold"><span class="Italics">MAXZIDE<span class="Sup">®</span></span></span><br><span class="Bold">(triamterene and</span><br><span class="Bold">hydrochlorothiazide</span><br><span class="Bold">tablets, USP)</span><br><span class="Bold">75 mg/</span><br><span class="Bold">50 mg</span></p>
<p><span class="Bold">Rx only    100 Tablets</span></p>
<p>Each tablet contains 75 mg<br>of triamterene, USP and 50 mg<br>of hydrochlorothiazide, USP.</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p><span class="Bold">Usual Adult Dosage: </span>See <br>accompanying prescribing <br>information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RBK0460A2</span></p>
<div class="Figure">
<a name="id361556352"></a><img alt="Maxzide 75 mg/50 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e92eda49-861e-4c79-b446-ec1213151d92&amp;name=image-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MAXZIDE-25 		
					</strong><br><span class="contentTableReg">maxzide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-0464</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRIAMTERENE</strong> (TRIAMTERENE) </td>
<td class="formItem">TRIAMTERENE</td>
<td class="formItem">37.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POWDERED CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (bow-tie shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MAXZIDE;B;M9</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-0464-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019129</td>
<td class="formItem">05/13/1988</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MAXZIDE 		
					</strong><br><span class="contentTableReg">maxzide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-0460</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRIAMTERENE</strong> (TRIAMTERENE) </td>
<td class="formItem">TRIAMTERENE</td>
<td class="formItem">75 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POWDERED CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (bow-tie shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MAXZIDE;B;M8</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-0460-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019129</td>
<td class="formItem">05/13/1988</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Pharmaceuticals Inc.
							(059295980)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0c2fa412-6689-48d7-917b-5c513a657f71</div>
<div>Set id: e92eda49-861e-4c79-b446-ec1213151d92</div>
<div>Version: 6</div>
<div>Effective Time: 20150921</div>
</div>
</div> <div class="DistributorName">Mylan Pharmaceuticals Inc.</div></p>
</body></html>
